Recent Updates
Recently added Catalysts
SPRY Positive Sentiment Score: 70/100

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

Thursday, February 9, 2023 1 min read
Key Takeaway: ARS Pharmaceuticals is set to participate in the SVB Securities Virtual Global Biopharma Conference 2023, with key executives scheduled for a fireside chat. The event is aimed at increasing visibility for the company's mission to assist at-risk patients with severe allergic reactions. The company is currently developing neffy®, an intranasal epinephrine product for treating Type I allergic reactions. The webcast will be available live and archived for 30 days on the company's investor website.

Market Sentiment Analysis

POSITIVE FACTORS

  • ARS Pharmaceuticals is actively participating in a prominent industry conference.
  • The company is focused on empowering patients and caregivers against serious allergic reactions.
  • Development of neffy® is aimed at improving treatment options for anaphylaxis.

Full Press Release Details

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today reported that Richard Lowenthal, M.Sc., MSEL, co-founder and chief executive officer, and Eric Karas, chief commercial officer, will participate in a fireside chat during the SVB Securities Virtual Global Biopharma Conference 2023 on Thursday, February 16, 2023 at 2:20 p.m. ET.
A live webcast will be available in the investor section of the company’s website at www.ars-pharma.com. The webcast will be archived for 30 days following the presentation.
About ARS Pharmaceuticals, Inc.
ARS is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing neffy® (previously referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit www.ars-pharma.com.
ARS Investor Contact:
justinc@ars-pharma.com

Frequently Asked Questions

What is the focus of ARS Pharmaceuticals, Inc.?

ARS Pharmaceuticals aims to empower at-risk patients against severe allergic reactions.

When will the SVB Securities Conference presentation occur?

The presentation is scheduled for February 16, 2023, at 2:20 p.m. ET.

What product is ARS developing for allergic reactions?

ARS is developing neffy®, an intranasal epinephrine product for Type I allergic reactions.

Where can I access the live webcast of the ARS presentation?

The live webcast will be available in the investor section of ARS's website.

How long will the presentation be archived online?

The webcast will be archived for 30 days after the presentation.

Tags: SPRY Viatris Investor Conferences Healthcare ARS Pharmaceuticals anaphylaxis SVB Securities biopharma conference neffy
Last updated: Feb 9, 2023